F12

F12 Full Name

coagulation factor XII (Hageman factor)

F12 Introduction

For many researchers and clinicians studying thrombosis and inflammation, understanding the role of the Coagulation Factor XII (F12) has become increasingly important as new therapeutic strategies aim to prevent pathological clot formation without increasing bleeding risk. Factor XII, also known as Hageman factor, is a plasma serine protease encoded by the F12 gene and primarily synthesized in the liver. It circulates in blood as an inactive zymogen and becomes activated upon contact with negatively charged surfaces such as exposed collagen, nucleic acids, or artificial biomaterials. Once activated to FXIIa, it initiates the intrinsic pathway of coagulation and also triggers the kallikrein–kinin system. Although factor XII participates in laboratory coagulation assays such as activated partial thromboplastin time (aPTT), its physiological role has long puzzled scientists because individuals with congenital FXII deficiency often exhibit prolonged clotting times In Vitro but do not show spontaneous bleeding In Vivo. This unique characteristic has attracted growing interest in the drug discovery field, especially for developing safer antithrombotic targets that minimize the bleeding complications commonly associated with conventional anticoagulants.

Functionally, factor XII acts as a molecular bridge between coagulation, inflammation, and innate immune responses. Upon activation, FXIIa converts prekallikrein into kallikrein and activates factor XI, amplifying the intrinsic coagulation cascade. At the same time, this activation promotes the generation of bradykinin through the kallikrein–kinin pathway, which contributes to vascular permeability, inflammatory signaling, and host defense mechanisms. These biological activities place factor XII at the intersection of thrombosis, vascular biology, and inflammatory disease processes. Recent population-scale genomic analyses have further highlighted its functional significance. A large multidimensional study using the UK Biobank and the NIH All of Us dataset demonstrated that partial loss of function or haploinsufficiency of the F12 gene is associated with a reduced risk of venous thromboembolism without increasing bleeding or infection susceptibility. This observation suggests that moderate suppression of factor XII activity could represent a promising therapeutic strategy for preventing pathological thrombosis while preserving normal hemostasis, an unmet need in current anticoagulant therapy.

Beyond thrombosis, emerging evidence links alterations in factor XII levels or activity to several disease contexts, including infectious diseases, hereditary coagulation abnormalities, and critical care outcomes. Clinical observations from intensive care cohorts have shown that reduced FXII levels at ICU admission may correlate with worse respiratory outcomes in severe COVID-19 patients, suggesting that factor XII dynamics could reflect underlying immune or coagulation dysregulation during systemic infection. Meanwhile, genetic studies continue to expand the mutation spectrum associated with congenital factor XII deficiency, including start codon variants that impair protein expression and lead to markedly reduced plasma FXII levels. Although such deficiencies are typically asymptomatic in terms of bleeding risk, they are often discovered through abnormal coagulation test results and may require careful clinical interpretation before surgical procedures. Epidemiological investigations in several populations have also identified asymptomatic FXII deficiency during routine preoperative screening, highlighting the importance of understanding genotype–phenotype relationships in this pathway. Collectively, these findings position factor XII as a compelling molecular target at the crossroads of thrombosis, inflammation, and genetic coagulation disorders, making it increasingly relevant for biomarker development and next-generation anticoagulant research.

Alternate Names for F12

F12; coagulation factor XII (Hageman factor); HAF; HAE3; HAEX; coagulation factor XII; Hageman factor; beta-factor XIIa part 1; beta-factor XIIa part 2; coagulation factor XIIa heavy chain; coagulation factor XIIa light chain;

• 1.Haj AK, et al.; Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis. Nat Commun. 2025, 16(1):8176.
  2.Alqahtany FS, et al.; Factor XII deficiency in asymptomatic Saudi population: A retrospective cohort study. Saudi J Biol Sci. 2021, 28(3):2004-2006.